secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001493152-25-025963
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 2.04, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant completes sale of Coflex/CoFix and Paradigm OUS to Companion Spine for $19.2M
--------------------------------------------------------------------------------

- Total consideration $19.2M: $11.0M cash plus $8.2M unsecured promissory note maturing Jan 15, 2026.
- Net cash proceeds used to prepay $8.0M of MidCap term loan; $14.4M remains outstanding, with up to $1.6M additional prepayment upon note repayment.
- Pro forma revenue for nine months ended Sep 30, 2025 would be $85.2M (vs $101.6M reported); net income $6.8M (vs $4.9M) including estimated $3.9M gain.
- CEO states net proceeds and operating cash flows expected to eliminate need for additional external capital.
- Divestiture represents Xtant's shift to focus on core biologics business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225025963/0001493152-25-025963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225025963/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer